Ertapenem: a new carbapenem

Bibliography

• SUNDELOF JG, HAJDU R, GILL CJ, THOMPSON R, ROSEN H, KROPP H: Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob. Agents Chemother. (1997) 41:1743–1748.
   PubMed Web of Science ®Google Scholar
• KOHLER J, DOORS KL, YOUNG K etal.: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum 13-lactamase- and extended-spectrum 13-lactamase-producing Klebsiella prieumorriae and Escherichia coil clinical isolates. Antimicrob. Agents Chemother. (1999) 43:1170–1176.
   Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. Antimicrob. Chemother. (1999) 43:703–706.
   Web of Science ®Google Scholar
• ODENHOLT I, LOWDIN E, CARS 0: In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. (1998) 42:2365–2370.
   PubMed Web of Science ®Google Scholar
• SCOTT PM, GILL CJ, SHUNGU DL, KROPP H: Comparative in vitro activity of L-749,345 against respiratory tract bacterial pathogens. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996). F121.
   Google Scholar
• PANKUCH GA, JACOBS MR, APPELBAUM PC: Antipneumococcal activity of MK-0826 (a new long-acting carbapenem) compared to nine other agents. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000). 387.
   Google Scholar
• ZHANEL GG, KARLOWSKY JA, PALATNICK LP, HOBAN DJ: hi vitro activity of MK-0826 against Canadian respiratory isolates of Streptococcus prieumorriae and Haemophilus irilluenzae. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000). 384.
   Google Scholar
• MOLAND ES, THOMSON KS: hi vitro activity of MK-0826 against 253 well characterized strains of enterobacteriaceae which produce ESBLs and/or AmpC 13-lactamases. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000). 382.
   Google Scholar
• GOLDSTEIN EJC, CITRON DM, MERRIAM CV, WARREN Y, TYRRELL KL: Comparative in vitro activites of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. (2000) 44:2389–2394.
   PubMed Web of Science ®Google Scholar
• WEXLER HM, MOLITORIS D, FINEGOLD SM: In vitro activities of ertapenem (L-749,345) against 363 strains of anaerobic bacteria. Antimicrob. Agents chemother. (2000) 44:2222-2224. KELLY LM, HOELLMAN DB, EDNIE LM etal.: Anti-anaerobic activity of MK-0826 (a new long-acting carbapenem) compared to six other agents. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000). 386.
   Google Scholar
• SHUNG DL, SCOTT T, GILL C, LYNCH L, ROSEN H, ZHAO PL, KROPP H. Preliminary interpretive criteria for susceptibiltiliy testing of L-749,345 (ZD 4433). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996). D–39.
   Google Scholar
• BARRY AL, FUCHS PC, BROWN SD: In vitro activity of carbapenem, MK-0826 (L-749,345), and provisional criteria for disk tests. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (24–27 September 1998). D–38.
   Google Scholar
• LIVERMORE DM, WARNER M, OAKTON K: Activity of MK-0826 versus P-lactamase producers. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000) 385.
   Google Scholar
• KOHLER J, DORSO K, PELAK BA et al: In vitro activity of the potent, broad-spectrum carbapenem L-749,345 against BDSBL- and ESBL-producing Escherichia coil and Klebsiella prieumorriae clinical isolates. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996) F122.
   Google Scholar
• JACOBY G, HAN P, TRAN J: Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant Gram-negative clinical pathogens. Antimicrob. Agents Chemother. (1997) 41:1830–1831.
   PubMed Web of Science ®Google Scholar
• THOMSON KS, MOLAND ES, BLACK JA, CHARTRAND SA: Standard and high inoculum MICs of MK-0826 in tests with ESBL, plasmid-mediated AmpC and multiple P-lactamase producing enterobacteriaceae. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000) 383.
   Google Scholar
• PELAK BA, GERCKENS LS, SCOTT PM et al: Antibacterial profile of L-749,345 (ZD-4433), a new potent 1-13-methyl carbapenem. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996) F119.
   Google Scholar
• DORSO K, KOHLER J, SILVER LL, KROPP H: Bactericidal effect of L-749,345 on Staphylococcus aureus and SerratM marcescens in the presence and absence of human serum. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996) F123.
   Google Scholar
• KOHLER J, DORSO K, YOUNG K, HIRSCH C, SILVER LL, KROPP H: Evaluation of resistance selection potential of the new carbapenem L-749,345 in 13-lactamase-producing Escherichia coil clinical isolates. 366 Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996) F124.
   Google Scholar
• FANG GD, ROSEN H, SCHELD WM: Comparative efficacy of L-749,345 (L-345) alone and in combination with vancomycin against highly penicillin-resistant Streptococcus prieumorriae (PRSP) experimental meningitis in rabbits. 4ah Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000) 1785.
   Google Scholar
• CRAIG WA. Pharmacokinetici pharmacodynamic parameters: Rationale for antibiotic dosing of mice and men. art Infer. Dis. (1998) 26:1–12.
   PubMed Web of Science ®Google Scholar
• VAN OGTROP ML, ANDES D, CRAIG WA: In vivo antimicrobial activity of MK-0826, a nes carbapenem, against various penicillin-resistant pneumococci. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (24–27 September 1998) F–48.
   Google Scholar
• VAN OGTROP ML, ANDES D, CRAIG WA: Irr vivo antimicrobial activity of MK-0826, a new carbapenem, against various gram-negative bacteria and Staphylococcus aureus. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (26–29 September 1999) 999.
   Google Scholar
• GILL CJ, JACKSON JJ, GERCKENS LS et al.: In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, ertapenem (L-749,345). Antimicrob. Agents Chemother. (1998) 42:1996–2001.
   PubMed Web of Science ®Google Scholar
• GERCKENS LS, PELAK BA, THOMPSON R, ROSEN H, KROPP H. Pharmacokinetic evaluation of L-749,345 (ZD 4433), a long acting parenteral carbapenem in rodents. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996) F127.
   Google Scholar
• WONG BK, BRUHIN PJ, LIN JH: Dose-dependent plasma clearance of ertapenem, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys. j Pharm. Sci. (1999) 88:277–280.
   PubMed Web of Science ®Google Scholar
• MAJUMDAR A, BIRK K, BLUM RA et al.: Pharmacokinetics of L-749,345, a carbapenem antibiotic, in healthy male and female volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996) F130.
   Google Scholar
• MAJUMDAR AK, BIRK KL, NEWAY W et al.: Single-dose pharmacokinetics and dose-proportionality of MK-0826, a once-daily carbapenem antibiotic, in healthy male and female volunteers. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (17–20 September 2000) 491.
   Google Scholar
• DE LEPELEIRE I, LAETHEM T, McCREA J et al.: Tissue penetration of MK-0826, a new once-daily parenteral carbapenem antibiotic, in young healthy volunteers. 10th European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden (28–31 May 2000) MoP244.
   Google Scholar
• YELLIN A, HESELTINEP, GILBERT DNet al.: Phase IIA randomized, double-blind, multicenter study of ertapenem v. Ceftriaxoneimetronidazole in the treatment of complicated intraabdominal infection (IAI), a preliminary analysis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (24–27 September 1998) MN–49.
   Google Scholar
• MOUTON JW, TOUZW DJ, HORREVORTS AM, VINKS AA: Comparative pharmacokinetics of the carbapenems: clinical implication. OM. Pharmacokinet. (2000) 39:185–201.
   PubMed Web of Science ®Google Scholar
• ALDRIDGE KE, ASHCRAFT D, DAVIS S, GELFAND M: Comparative in vitro activity of MK-0826 (L-749,345), a new carbapenem, against nosocomial isolates of Enterobacteriaceae. 10th European Congress of Clinical 11/licrobiology and Infectious Diseases. Stockholm, Sweden (28–31 May 2000) WeP54.
   Google Scholar
• JACOBY G, HAN P: Comparative in vitro activity of carbapenem L-749,345 (345) and other antimicrobials against multiresistant gram negative clinical pathogens. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (15–18 September 1996) F120.
   Google Scholar